Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jeff Ubben Helps to Recover Allison Transmission’s Face Value

Jeffrey Ubben‘s hedge fund, ValueAct Capital, did not disclose holding shares of Allison Transmission Holdings Inc. (NYSE:ALSN) in its latest 13F filing with the Securities and Exchange Commission. However, recently, Mr. Ubben has submitted a new filing with the SEC disclosing the ownership of 18,025,204 shares of the company. The position achieved represents a 9.9% of the company’s outstanding common stock, placing ValueAct Capital as the hedge fund with the largest position amongst those we track.


The recent disclosure comes just days before the Allison Transmission announced the sale of 15 million shares of its common stock by investment funds affiliated with Onex Corp and The Carlyle Group. The sale is expected to close on November 15th, while Allison Transmission will receive no proceeds, and the sponsors will continue to control a total of 111,892,500 shares, or approximately 61.4 percent of the company in question.

The move by Onex Corp and The Carlyle Group has been dubbed by some analysts as an insider bail out related to lower than expected performance, since Allison Transmission’s stock has underperformed in comparison with the S&P 500. Other analysts interpret the transaction as timely, pointing out that Onex Corp and The Carlyle Group will recover the initial investment and control over 50% of the firm.

In the end, the decision gives Ubben and ValueAct the opportunity to increase its stake in Allison. Most importantly, ValueAct’s recent disclosure is said to be timed to influence the transaction announced by the majority stakeholders. Interestingly, the disclosure had a positive impact on stock price, which rose by almost a dollar, recovering much of the loss registered at the end of October.

Disclosure: none

Recommended Reading:

Why Is Phil Frohlich Buying China Marine Food Group As It Delists From NYSE?

Why John Paulson and Other Big Investors Are Betting on Extended Stay America’s IPO

How The Debt Ceiling Increase Helped The Majority of Hedge Funds

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!